| Literature DB >> 29024533 |
Daniel Modin1, Morten Sengeløv1, Peter Godsk Jørgensen1,2, Niels Eske Bruun1,3, Flemming Javier Olsen1, Maria Dons1, Thomas Fritz Hansen1, Jan Skov Jensen1,2, Tor Biering-Sørensen1,2,4.
Abstract
AIMS: Quantification of systolic function in patients with atrial fibrillation (AF) is challenging. A novel approach, based on RR interval correction, to counteract the varying heart cycle lengths in AF has recently been proposed. Whether this method is superior in patients with systolic heart failure (HFrEF) with AF remains unknown. This study investigates the prognostic value of RR interval-corrected peak global longitudinal strain {GLSc = GLS/[RR^(1/2)]} in relation to all-cause mortality in HFrEF patients displaying AF during echocardiographic examination. METHODS ANDEntities:
Keywords: Atrial fibrillation; Global longitudinal strain; Heart failure with reduced ejection fraction; Risk stratification; Speckle tracking
Mesh:
Year: 2017 PMID: 29024533 PMCID: PMC5880669 DOI: 10.1002/ehf2.12220
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Clinical and echocardiographic characteristics
| All patients | Alive at follow‐up | Dead at follow‐up |
| |
|---|---|---|---|---|
| Clinical characteristics | ||||
|
| 151 | 111 | 40 | |
| Age (years) | 70.5 (9.2) | 69.7 (9.2) | 72.5 (8.9) | 0.10 |
| Male | 119 (78.8%) | 87 (78.4%) | 32 (80.0%) | 0.83 |
| Heart rate (b.p.m.) | 80.3 (20.4) | 80.4 (18.8) | 80.0 (24.4) | 0.91 |
| BMI (kg/m2) | 26.7 (5.1) | 27.0 (5.0) | 25.8 (5.5) | 0.19 |
| Diabetes mellitus | 14 (9.2%) | 12 (10.8%) | 2 (5.0%) | 0.28 |
| MAP (mmHg) | 93.4 (14.2) | 93.5 (14.9) | 93.2 (12.4) | 0.93 |
| Ischaemic cardiomyopathy | 65 (43%) | 50 (45.0%) | 15 (37.5%) | 0.41 |
| Total cholesterol (mmol/L) | 4.5 (1.0) | 4.5 (1.0) | 4.4 (1.1) | 0.50 |
| Angina pectoris | 27 (18) | 18 (16.2%) | 9 (22.5%) | 0.37 |
| CABG | 31 (21%) | 26 (23.4%) | 5 (12.5%) | 0.14 |
| Beta‐blockers | 104 (69%) | 74 (66.7%) | 30 (75.0%) | 0.33 |
| RAS blockade | 125 (83%) | 92 (82.9%) | 33 (82.5%) | 0.96 |
| Diuretics | 80 (53%) | 60 (54.1%) | 20 (50.0%) | 0.66 |
| Antiarrhythmics | 8 (5.0%) | 6 (5.4%) | 2 (5.0%) | 0.92 |
| Calcium channel blocker | 2 (1.0%) | 2 (1.8%) | 0 (0.0%) | 0.39 |
| Anticoagulants | 2 (1.3%) | 2 (1.8%) | 0 (0.0%) | 0.39 |
| Spironolactone | 17 (11.0%) | 12 (10.8%) | 5 (12.5%) | 0.77 |
| Echocardiography | ||||
| LVEF (%) | 26.2 (9.4) | 27.1 (8.6) | 23.7 (11.0) | 0.053 |
| RR interval (s) | 0.792 (0.190) | 0.890 (0.180) | 0.810 (0.220) | 0.47 |
| LVIDd (cm) | 5.7 (0.9) | 5.6 (0.8) | 5.7 (1.1) | 0.50 |
| LVMI (g/m2) | 117.5 (32.4) | 116.4 (33.1) | 120.3 (30.6) | 0.52 |
| LAVI (mL/m2) | 42.1 (19.0) | 40.2 (15.3) | 47.5 (26.0) | 0.035 |
| E (m/s) | 0.97 (0.300) | 0.97 (0.306) | 0.96 (0.281) | 0.93 |
| e′ (m/s) | 0.086 (0.026) | 0.087 (0.027) | 0.082 (0.021) | 0.32 |
| E/e′ | 11.9 (5.3) | 11.8 (5.39) | 12.4 (5.00) | 0.57 |
| DT (ms) | 159 (61) | 160 (54) | 159 (75) | 0.93 |
| TAPSE (cm) | 1.6 (0.5) | 1.6 (0.5) | 1.4 (0.5) | 0.016 |
| GLS (%) | −10.1 (3.6) | −10.5 (3.4) | −9.2 (3.9) | 0.056 |
| GCS (%) | −9.3 (3.5) | −9.7 (3.6) | −8.1 (2.9) | 0.022 |
| GLSc (%/s(1/2)) | −11.4 (3.9) | −11.8 (3.7) | −10.2 (4.3) | 0.022 |
| GCSc (%/s(1/2)) | −10.5 (4.2) | −11.1 (4.2) | −8.9 (3.7) | 0.007 |
BMI, body mass index; CABG, coronary artery bypass grafting; DT, E‐wave deceleration time; GCS, global circumferential strain; GCSc, RR‐corrected global circumferential strain {GCSc = GCS/[RR^(1/2)]}; GLS, global longitudinal strain; GLSc, RR‐corrected global longitudinal strain {GLSc = GLS/[RR^(1/2)]}; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal diameter at end‐diastole; LVMI, left ventricular mass index; MAP, mean arterial pressure; RAS, renin–angiotensin system; TAPSE, tricuspid annular plane systolic excursion.
Clinical and echocardiographic characteristics by tertiles of GLSc
|
Lowest tertile |
Middle tertile |
Highest tertile |
| |
|---|---|---|---|---|
| Clinical characteristics | ||||
|
| 50 | 50 | 51 | |
| Age (years) | 69.7 (8.5) | 71.5 (8.5) | 70.1 (10.4) | 0.82 |
| Male | 46 (92%) | 39 (78%) | 34 (67%) | 0.002 |
| Heart rate (b.p.m.) | 82.1 (24.0) | 79.2 (22.0) | 79.5 (15.0) | 0.52 |
| BMI (kg/m2) | 27.4 (5.5) | 26.8 (4.6) | 25.9 (5.1) | 0.14 |
| Diabetes mellitus | 7 (14%) | 6 (12%) | 1 (2%) | 0.08 |
| MAP (mmHg) | 92.6 (13.3) | 93.5 (13.4) | 94.0 (16.1) | 0.62 |
| Ischaemic cardiomyopathy | 22 (44%) | 24 (48%) | 19 (37%) | 0.49 |
| Total cholesterol (mmol/L) | 4.4 (1.1) | 4.6 (1.0) | 4.5 (1.0) | 0.76 |
| Angina pectoris | 8 (16%) | 10 (20%) | 9 (18%) | 0.83 |
| CABG | 11 (22%) | 12 (24%) | 8 (16%) | 0.43 |
| Beta‐blockers | 32 (64%) | 35 (70%) | 37 (73%) | 0.36 |
| RAS blockade | 44 (88%) | 37 (74%) | 44 (86%) | 0.83 |
| Diuretics | 25 (50%) | 25 (50%) | 30 (59%) | 0.38 |
| Antiarrhythmics | 3 (6%) | 2 (4%) | 3 (6%) | 0.98 |
| Calcium channel blockers | 1 (2%) | 0 (0%) | 1 (2%) | 0.99 |
| Anticoagulants | 1 (2%) | 1 (2%) | 0 (0%) | 0.38 |
| Spironolactone | 9 (18%) | 4 (8%) | 4 (8%) | 0.11 |
| Echocardiography | ||||
|
| 50 | 50 | 51 | |
| LVEF (%) | 18.6 (7.1) | 26.1 (7.5) | 33.6 (6.8) | <0.001 |
| RR interval (s) | 0.792 (0.211) | 0.813 (0.203) | 0.781 (0.150) | 0.87 |
| LVIDd (cm) | 6.2 (0.9) | 5.6 (0.75) | 5.2 (0.8) | <0.001 |
| LVMI (g/m2) | 125 (34) | 122 (29) | 105 (31.0) | 0.001 |
| LAVI (mL/m2) | 46.6 (17.7) | 40.0 (12.6) | 40.1 (24.2) | 0.08 |
| E (m/s) | 0.98 (0.25) | 0.95 (0.29) | 0.97 (0.36) | 0.87 |
| e′ (m/s) | 0.080 (0.021) | 0.091 (0.032) | 0.100 (0.031) | 0.035 |
| E/e′ | 12.8 (5.3) | 12.3 (6.3) | 10.5 (3.8) | 0.046 |
| DT (ms) | 137 (50) | 160 (68) | 182 (55) | <0.001 |
| TAPSE (cm) | 1.5 (0.4) | 1.5 (0.5) | 1.8 (0.5) | 0.002 |
| GLS (%) | −6.5 (1.9) | −10.0 (1.5) | −13.8 (2.2) | <0.001 |
| GCS (%) | −7.9 (3.5) | −9.5 (3.0) | −10.5 (3.6) | <0.001 |
| GCSc (%/s(1/2)) | −9.0 (3.7) | −10.8 (3.8) | −11.9 (4.5) | 0.001 |
BMI, body mass index; CABG, coronary artery bypass grafting; DT, E‐wave deceleration time; GCS, global circumferential strain; GCSc, RR‐corrected global circumferential strain {GCSc = GCS/[RR^(1/2)]}; GLS, global longitudinal strain; GLSc, RR‐ corrected global longitudinal strain {GLSc = GLS/[RR^(1/2)]}; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal diameter end‐diastole; LVMI, left ventricular mass index; MAP, mean arterial pressure; RAS, renin–angiotensin system; TAPSE, tricuspid annular plane systolic excursion.
Cox regression models
| Hazard ratio |
|
| |
|---|---|---|---|
| Univariable | |||
| LAVI (per increasing mL/m2) | HR 1.02, 95% CI 1.00–1.03 | 0.545 | 0.036 |
| TAPSE (per increasing cm) | HR 0.43, 95% CI 0.20–0.89 | 0.634 | 0.023 |
| GCS (per decreasing %) | HR 1.14, 95% CI 1.03–1.27, | 0.636 | 0.015 |
| GLSc (per decreasing %/s(1/2)) | HR 1.12, 95% CI 1.02–1.22 | 0.636 | 0.014 |
| GCSc (per decreasing %/s(1/2)) | HR 1.14, 95% CI 1.04–1.26 | 0.645 | 0.006 |
| Multivariable (age, sex, MAP, and heart rate) | |||
| LAVI (per increasing mL/m2) | HR 1.01, 95% CI 1.00–1.03 | 0.601 | 0.081 |
| TAPSE (per increasing cm) | HR 0.46, 95% CI 0.21–0.98 | 0.642 | 0.045 |
| GCS (per decreasing %) | HR 1.18, 95% CI 1.04–1.33 | 0.659 | 0.011 |
| GLSc (per decreasing %/s(1/2)) | HR 1.17, 95% CI 1.05–1.31 | 0.681 | 0.005 |
| GCSc (per decreasing %/s(1/2)) | HR 1.19, 95% CI 1.06–1.33 | 0.671 | 0.003 |
| Multivariable (age, sex, MAP, heart rate, LAVI, and E/e′) | |||
| TAPSE (per increasing cm) | HR 0.46, 95% CI 0.20–1.06 | 0.625 | 0.068 |
| GCS (per decreasing %) | HR 1.18, 95% CI 1.04–1.33 | 0.659 | 0.011 |
| GLSc (per decreasing %/s(1/2)) | HR 1.17, 95% CI 1.05–1.31 | 0.681 | 0.005 |
| GCSc (per decreasing %/s(1/2)) | HR 1.19, 95% CI 1.06–1.33 | 0.671 | 0.003 |
CI, confidence interval; GCS, global circumferential strain; GCSc, RR‐corrected global circumferential strain {GCSc = GCS/[RR^(1/2)]}; GLSc, RR‐corrected global longitudinal strain {GLSc = GLS/[RR^(1/2)]}; LAVI, left atrial volume index; MAP, mean arterial pressure; TAPSE, tricuspid annular plane systolic excursion.
Figure 1The curves display the cumulative survival of the population stratified into tertiles of corrected global longitudinal strain (GLSc) as a function of time from examination. The red curve depicts the cumulative survival of patients in the lowest tertile of GLSc. The green curve depicts the cumulative survival of patients in the highest tertile of GLSc. The blue curve depicts the cumulative survival of patients in the middle tertile of GLSc. CI, confidence interval; HR, hazard ratio.